In the realm of value-based oncology care, the erudite Jason Bergsbaken, PharmD, MBA, BCOP, shines a light on the labyrinthine operational challenges. He deftly underscores the delicate equilibrium required to harmonize standardized treatment pathways with the malleability essential for personalized, biomarker-driven care.
At a recent gathering under the aegis of the Institute for Value-Based Medicine®, Jason Bergsbaken, PharmD, MBA, BCOP, delved into the convoluted terrain of operational and billing intricacies entwined with the implementation of value-based initiatives in oncology pharmacy, particularly in the realm of biosimilars. As the interim manager of oncology pharmacy at UW Health and a clinical assistant professor at the University of Wisconsin-Madison School of Pharmacy in Madison, Bergsbaken astutely pointed out the variegated definitions of value across patients, providers, health systems, and payers, making alignment a formidable task. This discourse marks the second episode in a series featuring Bergsbaken.
The advent of biosimilar adoption has heralded substantial advantages but has also unfurled operational hurdles, including payer-specific mandates on product usage, the conundrum of inventory management, and the burgeoning complexity of prior authorization processes, as highlighted by Bergsbaken. These hurdles demand significant resources and a harmonized effort between prior authorization teams and frontline staff to ensure the seamless delivery of care to patients in a timely fashion.
Bergsbaken also elucidated on the delicate balance between standardized, pathway-driven care and the imperative for personalized, biomarker-guided treatment, especially in the context of rare or late-stage cancer scenarios. His institution meticulously oversees formulary decisions through a multi-disciplinary review process in alignment with the National Comprehensive Cancer Network (NCCN) and FDA directives. Simultaneously, they allow for individualized regimen reviews by peers to accommodate unique clinical circumstances. This dual-pronged approach aims to uphold the safety and consistency of standardized care while affording the necessary flexibility for tailored treatment decisions.
Operational and billing challenges loom large when it comes to the implementation of value-based initiatives. The multifaceted nature of defining value, encompassing outcomes juxtaposed with costs, adds layers of complexity. The divergent perceptions of value among stakeholders within the intricate healthcare landscape further compound the challenge. Biosimilars, while pivotal in advancing healthcare, introduce their own set of challenges. Payer-specific mandates and the labyrinthine prior authorization processes pose daily conundrums, necessitating a deft operational dance to navigate these complexities efficiently.
Pathway adherence stands at the core of value-based care, yet the need for personalized, biomarker-driven treatment cannot be overlooked, especially in challenging scenarios like rare or late-stage cancers. Institutions, including ours, maintain a tight grip on formulary decisions, leveraging guidelines from esteemed bodies like the NCCN and FDA. However, we also recognize the importance of accommodating personalized treatment approaches through a patient-specific regimen review process. This tailored approach, validated through peer scrutiny, ensures that patient-centric needs are met without compromising on the safety and efficacy benchmarks set by standardized care pathways.
In the ceaseless whirlwind of healthcare policy, cost dynamics, and the pursuit of value, staying abreast of the latest insights becomes paramount. Subscribing to expert platforms like AJMC can offer invaluable perspectives at the nexus of clinical care and health economics. Engaging with such resources equips healthcare professionals with the tools to navigate the ever-evolving healthcare landscape effectively, ensuring optimal patient outcomes and operational efficiency.
- Embrace the complexity of biosimilar mandates and prior authorization processes in value-based care
- Strive for a delicate balance between standardized care pathways and personalized treatment approaches
- Leverage expert insights to navigate the evolving healthcare landscape with finesse
- Prioritize patient-centric care while upholding the safety and consistency standards of standardized care pathways
- Collaborate across disciplines to optimize operational efficiency and ensure timely patient care
Tags: immunotherapy
Read more on ajmc.com